New hope for aggressive uterine cancer: targeted drug trial shows promise
NCT ID NCT03668340
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing tumor growth. About 49 participants with two aggressive types of uterine cancer will be enrolled to see if the drug shrinks tumors or delays progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?
- Can a simple blood test predict leukemia risk after cancer therapy?
- New drug aimed at folate receptor shows promise for tough endometrial cancer
- Vitamins e and CoQ10 tested as shield against radiation damage
- New drug combo takes on advanced cancers in early trial
- Experimental combo targets Chemo-Resistant cancers